TY - JOUR
T1 - Updates in the Pharmacotherapy of Pulmonary Hypertension in Patients with Heart Failure with Preserved Ejection Fraction
AU - Segovia, Fernando
AU - Garcia, Hernando
AU - Alkhateeb, Haider
AU - Mukherjee, Debabrata
AU - Nickel, Nils
N1 - Publisher Copyright:
© 2023 Bentham Science Publishers.
PY - 2023
Y1 - 2023
N2 - Pulmonary hypertension (PH) associated with left heart disease (LHD) is a complex cardiopulmonary condition where a variable degree of pulmonary congestion, arterial vasocon-striction and vascular remodeling can lead to PH and right heart strain. Right heart dysfunction has a significant prognostic impact on these patients. Therefore, preserving right ventricular (RV) function is an important treatment goal. However, the treatment of PH in patients with left heart disease has produced conflicting evidence. The transition from pure LHD to LHD with PH is a continuum and clinically challenging. The heart failure with preserved ejection fraction (HFpEF) patient population is heterogeneous when it comes to PH and RV function. Appropriate clinical and hemodynamic phenotyping of patients with HFpEF and concomitant PH is paramount to making the appropriate treatment decision. This manuscript will summarize the current evidence for the use of pulmonary arterial vasodilators in patients with HFpEF.
AB - Pulmonary hypertension (PH) associated with left heart disease (LHD) is a complex cardiopulmonary condition where a variable degree of pulmonary congestion, arterial vasocon-striction and vascular remodeling can lead to PH and right heart strain. Right heart dysfunction has a significant prognostic impact on these patients. Therefore, preserving right ventricular (RV) function is an important treatment goal. However, the treatment of PH in patients with left heart disease has produced conflicting evidence. The transition from pure LHD to LHD with PH is a continuum and clinically challenging. The heart failure with preserved ejection fraction (HFpEF) patient population is heterogeneous when it comes to PH and RV function. Appropriate clinical and hemodynamic phenotyping of patients with HFpEF and concomitant PH is paramount to making the appropriate treatment decision. This manuscript will summarize the current evidence for the use of pulmonary arterial vasodilators in patients with HFpEF.
KW - combined pre-and post-capillary pulmonary hypertension
KW - heart failure with preserved ejection fraction
KW - left heart disease
KW - Pulmonary hypertension
KW - pulmonary vasodilators
UR - http://www.scopus.com/inward/record.url?scp=85181438182&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85181438182&partnerID=8YFLogxK
U2 - 10.2174/011871529X258234230921112507
DO - 10.2174/011871529X258234230921112507
M3 - Short survey
C2 - 37921162
AN - SCOPUS:85181438182
SN - 1871-529X
VL - 23
SP - 215
EP - 225
JO - Cardiovascular and Hematological Disorders - Drug Targets
JF - Cardiovascular and Hematological Disorders - Drug Targets
IS - 4
ER -